OVER 1,100 ADVAC ALUMNI WORLDWIDE

Through alumni get-together meetings and a variety of online resources (website), ADVAC continues to bring together vaccinologists throughout the world to discuss the major challenges of the day. The relationships forged at ADVAC remain strong through meetings organized in parallel with international conferences/meetings such as those of the Scientific Advisories Group of Experts (SAGE), the European Society for Paediatric Infectious Diseases (ESPID), the Infectious Disease Society of America (IDSA) and the Global NITAG Network (GNN). In the future collaboration will also take place in the context of Regional Immunization Programme Managers’ meetings.

For 20 years, ADVAC has provided senior decision-makers and scientists in the field of vaccines with a comprehensive overview of the latest advances, from immunology to vaccine development, including clinical trials. The social, economic, political and ethical issues of vaccination are also addressed during the lectures, which are given by a faculty of leading global experts.

WHO SHOULD APPLY?

• Scientists and decision-makers involved in vaccine development, in the elaboration of new vaccination strategies or in policy decisions relating to the introduction of new vaccines in public health programmes, at national or international levels.

• For both the public and private sectors.

Apply online through www.advac.org

Deadline: 15 November 2019 at 12:00 GMT.

APPLICATIONS

Applications will be selected by the International Scientific Committee, according to their:

• Educational background,
• Involvement in vaccinology,
• Decision-making responsibility in vaccinology,
• Expected impact of the Course at personal, institutional and national levels (maximum one participant per institution).

SELECTION CRITERIA

Participants (maximum 75) will be selected by the international Scientific Committee, according to their:

• Educational background,
• Involvement in vaccinology,
• Decision-making responsibility in vaccinology,
• Expected impact of the Course at personal, institutional and national levels (maximum one participant per institution).

COURSE FEES

Accommodation fees (including all meals):
€2,600

Registration fees
• Participants from academic/governmental institutions & NGOs benefit from reduced fees: €1,600 (VAT included)
• Participants from industry: €4,200
• Other industry participants: €9,200

The fees include tuition and course materials for the full period of the course. If selected, participants will be required to pay all fees in full to confirm their participation.

Fellowships:
Fellowships covering travel expenses, registration and accommodation fees will be available for participants from low and middle income countries (with the support of the Bill & Melinda Gates Foundation). Other fellowships/scholarships will be provided by ESPID, EDCTP and EDCTP.

VENUE

The course will be held at the Mérieux Foundation conference centre at Les Pensières, an eco-hotel located on the scenic banks of Lake Annecy (France). Accommodation will be arranged in nearby hotels.

CONTACT

advac@unige.ch

See additional info on:
www.advac.org • www.fondation-merieux.org

Organized by
The Mérieux Foundation and University of Geneva

with the co-sponsorship of
• Bill & Melinda Gates Foundation
• Centers for Disease Control and Prevention (CDC)
• European & Developing Countries Clinical Trials Partnership (EDCTP)
• European Society for Paediatric Infectious Diseases (ESPID)
• Johns Hopkins Bloomberg School of Public Health
• National Foundation for Infectious Diseases (NFID)
• National Institutes of Health (NIH/NIAID-USA) and Fogarty International Center
• World Health Organization
Objective: to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the field, from immunology to vaccine development, including clinical trials and the social, economic, political and ethical issues of vaccination.

PROVISIONAL PROGRAMME

SESSION 1

THE MULTIFACETED NATURE OF VACCINE ADVISORY GROUPS
- How to develop a new programme of immunization
- Access to vaccines in GAVI countries and at global level
- Are vaccines always cost-effective?
- Linkages between vaccinology and individual and collectives

SESSION 2

NEW VACCINES: WHAT NEXT?
- How are vaccine responses evolved?
- Immunological track for responses to vaccines
- Immunological rationale of immunity
- Vaccine and immunological memory

SESSION 3

DECISION-MAKING IN VACCINE R&D
- New approaches to vaccine development and delivery
- How to account for adverse events
- Engaging clinical research to vaccine development
- Vaccine regulatory framework

SESSION 4

ASSESSING VACCINES IN CLINICAL TRIALS (I)
- Sequential phases of clinical trials and overview of phases to be considered
- How to manage clinical challenges and analyze the results of extended phase trials
- How to design a phase II trial

SESSION 5

ASSESSING VACCINES IN CLINICAL TRIALS (II)
- Lessons from pivotal studies in the prophylactic vaccines
- Clinical trials: risk of data and safety
- Thorough analysis (Vaccine Safety
- Developing and analyzing the results of extended phase trials

SESSION 6

SPECIAL TOPIC: VACCINE SAFETY
- Lessons from previous adverse events of vaccination and prevention of causal misunderstandings
- Immunological efficacy of vaccines
- Population-based post-licensure surveillance
- Interactions safety in developing country vaccine programs
- Vaccine hindering and risk communication: overview

SESSION 7

ECOSYSTEM ETHICAL ISSUES
- Ethical issues related to clinical trials
- Group exchange

SESSION 8

INTERVENTION DECISION-MAKING INTO VACCINATION PROGRAMMES
- Lessons learned and public health lessons
- Role of epidemiology and health economics
- Development of national vaccination policies and actions
- Approaches to the decision-making process
- Adjusting vaccination strategies
- Design of healthcare approaches, and its important for vaccination
- Vaccination and the elderly
- Vaccination and the elderly
- Vaccination and the elderly
- Vaccination and the elderly
- Vaccination and the elderly
- Vaccination and the elderly

SESSION 9

DECISION-MAKING FACED THE MEDIA
- Introduction to media dynamics
- How to deal with vaccinology-related messages to different interest groups

SESSION 10

FACING THE MEDIA
- Introduction to media dynamics
- How to deal with vaccinology-related messages to different interest groups

SAMPLE OF REGULAR LECTURERS

PHILIPPE DUCLOS
icddr,b, Bangladesh

RON DAGAN
Noni McDonald

JOHN CLEMENS
NIAID, NIH, USA

Cristina Cassetti
Children's Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

NICK ANDREWS
Imperial College London, UK

ADAM FINN
Seattle Children's Hospital, USA

JANET ENGLUND
University of California in San Francisco, USA

KARI JOHANSEN
WHO, Switzerland

CAROLE HEILMAN
Boston Children's Hospital, USA

MARTIN FRIEDE
Development/Training of National Vaccination Policies, WHO, South Africa

DAVID GOLDBLATT
Fogarty International Center, NIH, USA

ROGER GLASS
WHO, Switzerland

BERNARD FRITZELL
WHO, Switzerland

ADAM FINN
Seattle Children's Hospital, USA

JULIET BRYANT
Bill & Melinda Gates Foundation

ANANDA BANDYOPADHYAY
Children’s Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

SCIENTIFIC COMMITTEE

KETAN SHAH
London School of Hygiene & Tropical Medicine, UK

GUIDO PASSAl
London School of Hygiene & Tropical Medicine, UK

CATHERINE SLACK
University of Geneva, Switzerland

ROGER GLASS
WHO, Switzerland

BRAD ROBINSON
Boston Children's Hospital, USA

KARI JOHANSEN
WHO, Switzerland

CAROLE HEILMAN
Boston Children's Hospital, USA

DAVID GOLDBLATT
Fogarty International Center, NIH, USA

ROGER GLASS
WHO, Switzerland

ADAM FINN
Seattle Children's Hospital, USA

JULIET BRYANT
Bill & Melinda Gates Foundation

ANANDA BANDYOPADHYAY
Children’s Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

JULIET BRYANT
Bill & Melinda Gates Foundation

ANANDA BANDYOPADHYAY
Children’s Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

JULIET BRYANT
Bill & Melinda Gates Foundation

ANANDA BANDYOPADHYAY
Children’s Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

JULIET BRYANT
Bill & Melinda Gates Foundation

ANANDA BANDYOPADHYAY
Children’s Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

JULIET BRYANT
Bill & Melinda Gates Foundation

ANANDA BANDYOPADHYAY
Children’s Hospital Colorado, USA

EDWIN ASTURIAS
Public Health England, UK

JULIET BRYANT
Bill & Melinda Gates Foundation